Graves' ophthalmopathy and gene polymorphisms in interleukin-1α, interleukin-1β, interleukin-1 receptor and interleukin-1 receptor antagonist

Clinical and Experimental Ophthalmology

Volumn 37, Issue 6, 2009, Pages 614-619

  Khalilzadeh, Omid ^a,b   Anvari, Mehdi ^a,b   Esteghamati, Alireza ^a   Mahmoudi, Mahdi ^b,c   Tahvildari, Maryam ^b   Rashidi, Armin ^a   Khosravi, Farideh ^c   Amirzargar, Aliakbar ^b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokine; Gene; Graves' disease; Graves' ophthalmopathy; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENDOCRINE OPHTHALMOPATHY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE OF ONSET; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAVES OPHTHALMOPATHY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-1;

EID: 68349160643     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02093.x     Document Type: Article

References (53)

1. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-48.
2. Gianoukakis AG, Smith TJ. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes 2008; 15: 446-52.
3. Esteghamati A, Khalilzadeh O, Mobarra Z et al. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. Eur J Int Med 2009; 20: 424-8.
4. Heufelder AE, Bahn RS, Smith TJ. Regulation by glucocorticoids of interferon gamma-induced HLA-DR antigen expression in cultured human orbital fibroblasts. Clin Endocrinol (Oxf) 1992; 37: 59-63.
5. Kahaly G, Hansen C, Felke B, Dienes HP. Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol 1994; 73: 53-62.
6. Weetman AP. Thyroid-associated eye disease: Pathophysiology. Lancet 1991; 338: 25-8.
7. Bahn RS, Heufelder AE. Retroocular fibroblasts: Important effector cells in Graves' ophthalmopathy. Thyroid 1992; 2: 89-94.
8. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996; 81: 449-52.
9. Natt N, Bahn RS. Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 1997; 26: 129-36.
10. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106-13.
11. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20: S1-13.
12. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732-4.
13. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2008.
14. Sarial S, Shokrgozar MA, Amirzargar A et al. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol 2008; 7: 37-40.
15. Ravindran JS, Owen P, Lagan A et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology (Oxford) 2004; 43: 22-6.
16. Parks CG, Cooper GS, Dooley MA et al. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: A population based study in the southeastern United States. Ann Rheum Dis 2004; 63: 91-4.
17. Alayli G, Aydin F, Coban AY et al. T helper 1 type cytokines polymorphisms: Association with susceptibility to Behcet's disease. Clin Rheumatol 2007; 26: 1299-305.
18. Carreira PE, Gonzalez-Crespo MR, Ciruelo E et al. Polymorphism of the interleukin-1 receptor antagonist gene: A factor in susceptibility to rheumatoid arthritis in a Spanish population. Arthritis Rheum 2005; 52: 3015-19.
19. Harrison P, Pointon JJ, Chapman K, Roddam A, Wordsworth BP. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1768-70.
20. Zeyrek D, Demir E, Alpman A, Ozkinay F, Gulen F, Tanac R. Association of interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in Turkish children with atopic asthma. Allergy Asthma Proc 2008; 29: 468-74.
21. Abazis-Stamboulieh D, Oikonomou P, Papadoulis N, Panayiotidis P, Vrakidou E, Tsezou A. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 2007; 48: 2196-203.
22. Blakemore AI, Watson PF, Weetman AP, Duff GW. Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab 1995; 80: 111-15.
23. Kammoun-Krichen M, Bougacha-Elleuch N, Makni K et al. Association analysis of interleukin gene polymorphisms in autoimmune thyroid diseases in the Tunisian population. Eur Cytokine Netw 2007; 18: 196-200.
24. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 2000; 85: 1984-8.
25. Chen RH, Chen WC, Chang CT, Tsai CH, Tsai FJ. Interleukin-1-beta gene, but not the interleukin-1 receptor antagonist gene, is associated with Graves' disease. J Clin Lab Anal 2005; 19: 133-8.
26. Cuddihy RM, Bahn RS. Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population. J Clin Endocrinol Metab 1996; 81: 4476-8.
27. Muhlberg T, Kirchberger M, Spitzweg C, Herrmann F, Heberling HJ, Heufelder AE. Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population. Eur J Endocrinol 1998; 138: 686-90.
28. Werner SC. Modification of the classification of the eye changes of Graves' disease: Recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977; 44: 203-4.
29. Yin X, Latif R, Bahn R, Tomer Y, Davies TF. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid 2008; 18: 1201-6.
30. Villanueva R, Inzerillo AM, Tomer Y et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: No role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000; 10: 791-8.
31. Ichimura M, Kaku H, Fukutani T et al. Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population. Thyroid 2008; 18: 625-30.
32. Hiromatsu Y, Fukutani T, Ichimura M et al. Interleukin-12B gene polymorphism does not confer susceptibility to Graves' ophthalmopathy in Japanese population. Endocr J 2006; 53: 753-9.
33. Chong KK, Chiang SW, Wong GW et al. Association of CTLA-4 and IL-13 gene polymorphisms with Graves' disease and ophthalmopathy in Chinese children. Invest Ophthalmol Vis Sci 2008; 49: 2409-15.
34. Mukai T, Hiromatsu Y, Ichimura M et al. Lack of association of interleukin-18 gene polymorphisms with susceptibility of Japanese populations to Graves' disease or Graves' ophthalmopathy. Thyroid 2006; 16: 243-8.
35. Han SZ, Zhang SH, Li R, Zhang WY, Li Y. The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Int J Immunogenet 2006; 33: 281-7.
36. Zhang Q, Yang YM, Lv XY. Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene. J Zhejiang Univ Sci B 2006; 7: 887-91.
37. Bednarczuk T, Hiromatsu Y, Fukutani T et al. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur J Endocrinol 2003; 148: 13-18.
38. Boyle B, Koranyi K, Patocs A et al. Polymorphisms of the glucocorticoid receptor gene in Graves ophthalmopathy. Br J Ophthalmol 2008; 92: 131-4.
39. Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: The IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2008; 93: 1077-81.
40. Syed AA, Simmonds MJ, Brand OJ, Franklyn JA, Gough SC, Heward JM. Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves ophthalmopathy. Clin Endocrinol (Oxf) 2007; 67: 663-7.
41. Bednarczuk T, Hiromatsu Y, Seki N et al. Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. Hum Immunol 2004; 65: 632-9.
42. Kamizono S, Hiromatsu Y, Seki N et al. A polymorphism of the 5′ flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese. Clin Endocrinol (Oxf) 2000; 52: 759-64.
43. Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci 1992; 33: 2037-42.
44. Tandon N, Yan SL, Morgan BP, Weetman AP. Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology 1994; 81: 643-7.
45. Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2004; 61: 405-13.
46. Heufelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 2000; 1: 87-95.
47. Rasmussen AK, Diamant M, Blichert-Toft M, Bendtzen K, Feldt-Rasmussen U. The effects of interleukin-1beta (IL-1beta) on human thyrocyte functions are counteracted by the IL-1 receptor antagonist. Endocrinology 1997; 138: 2043-8.
48. Muhlberg T, Heberling HJ, Joba W, Schworm HD, Heufelder AE. Detection and modulation of interleukin-1 receptor antagonist messenger ribonucleic acid and immunoreactivity in Graves' orbital fibroblasts. Invest Ophthalmol Vis Sci 1997; 38: 1018-28.
49. Muhlberg T, Joba W, Spitzweg C, Schworm HD, Heberling HJ, Heufelder AE. Interleukin-1 receptor antagonist ribonucleic acid and protein expression by cultured Graves' and normal orbital fibroblasts is differentially modulated by dexamethasone and irradiation. J Clin Endocrinol Metab 2000; 85: 734-42.
50. Cominelli F, Pizarro TT. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther 1996; 10(Suppl. 2): 49-53. discussion 4.
51. Chistyakov DA, Savost'anov KV, Turakulov RI et al. Complex association analysis of graves disease using a set of polymorphic markers. Mol Genet Metab 2000; 70: 214-18.
52. Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease. Rheumatology (Oxford) 2003; 42: 860-4.
53. Iacoviello L, Di Castelnuovo A, Gattone M et al. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol 2005; 25: 222-7.